Join

Compare · BIAF vs CRL

BIAF vs CRL

Side-by-side comparison of bioAffinity Technologies Inc. (BIAF) and Charles River Laboratories International Inc. (CRL): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BIAF and CRL operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
  • CRL is the larger of the two at $8.98B, about 1247.6x BIAF ($7.2M).
  • Over the past year, BIAF is down 81.3% and CRL is up 26.5% - CRL leads by 107.8 points.
  • CRL has been more active in the news (20 items in the past 4 weeks vs 5 for BIAF).
  • CRL has more recent analyst coverage (25 ratings vs 0 for BIAF).
PerformanceBIAF-81.28%CRL+26.51%
2025-06-09+0.00%2026-06-08
MetricBIAFCRL
Company
bioAffinity Technologies Inc.
Charles River Laboratories International Inc.
Price
$1.62-5.81%
$186.54+2.88%
Market cap
$7.2M
$8.98B
1M return
-23.58%
+2.54%
1Y return
-81.28%
+26.51%
Industry
Biotechnology: Commercial Physical & Biological Resarch
Biotechnology: Commercial Physical & Biological Resarch
Exchange
NASDAQ
NYSE
IPO
2022
2000
News (4w)
5
20
Recent ratings
0
25
CRL

Charles River Laboratories International Inc.

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.

Latest BIAF

Latest CRL